Aperio Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Aperio Group’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,402	Closed	-$45K	–	2194
2016 Q4	$45K	Buy	+1,402	New	+$59.8K	﹤0.01%	2106

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aperio Group's MACK Position: Q1 2017 in Review

Aperio Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 1,402 shares — an estimated $45K sold.

Aperio Group first reported a position in MACK in Q4 2016 and held it in 1 quarter. The position peaked at $45K in Q4 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

Aperio Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Aperio Group sold 1,402 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $45K.
Aperio Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
Aperio Group's Merrimack Pharmaceuticals, Inc. position peaked at $45K in Q4 2016.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Aperio Group's 13F filing for Q1 2017, filed 5 May 2017.